		<b>TH AND HUMAN SERVIC</b> G ADMINISTRATION	ES	
DISTRICT ADDRESS AND PHON	D PHONE NUMBER DATE		OF INSPECTION 2017-5/18/2017*	
Bothell, WA	98021 FEINUM			
	0340 Fax:(425)302-0404		6960	
NAME AND TITLE OF INDIVIDUA		l	-	
Mary K. Moe	, Sr Director of Operations	L other appear		_
	Enterprises, Inc.	STREET ADDRESS  728 134th St SW , Suite 128  TYPE ESTABLISHMENT INSPECTED.		
Everett, WA		Producer of ste	rile drug produ	ıcts
observations, and do observation, or have action with the FDA	observations made by the FDA representative(s) not represent a final Agency determination regainplemented, or plan to implement, corrective a representative(s) during the inspection or submittact FDA at the phone number and address about	arding your compliance. If y action in response to an obs it this information to FDA a	you have an objection re servation, you may discu	garding an ss the objection or
DURING AN INSPEC	CTION OF YOUR FIRM I OBSERVED:			
Disinfecting age	ents used in the ISO 5 area are not s	terile. Specifically,		
engineering con ISO 7 (b) (4)	ermicidal detergent is used (b) (4) in tarrols) as well as all work surfaces in . The germicidal detergent is rotated non-sterile (b) (4) is used in	n the ISO 7 (b) (4	4) ISO 7 (b)	nary ) (4) and is used in
OBSERVATIO		uga Spaoifiaelly		
A non-sterile to	ol was used in the production of dru	igs. Specifically,		
On 5/9/17 a reu (b)(6),(b)(7)(C) TPN 3 (b) (the reusable	3 in 1 in the ISO 5 (b) (4) lamina	r flow hood (LFH) # icles were observed l	rved used in the pr (b) (4 petween the (l	
OBSERVATIO	ON 3			
	iscoloration was observed in the ISO	O 5 area. Specifically	′,	
	AMEN	DMENT 2		
	EMPLOYEE(S) SIGNATURE			DATE ISSUED
SEE REVERSE	Tracy K Li, Investigator		5/19/2017	5/19/2017
OF THIS PAGE			Tracy K Li	
			Investigator Signed by: Tracy K. Li -S	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	SPECTIONAL OBSERVATI	ONS	PAGE 1 OF 5 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHON			DATE(S) OF INSPECTION  5/8/2017-5/18/2017*		
Bothell, WA 9			FEI NUMBER		
(425)302-0340	2-0340 Fax:(425)302-0404		3009486	960	
NAME AND TITLE OF INDIVIDUA	L TO WHOM REPORT ISSUED				
	Sr Director of Operations				
Option Care F	re Enterprises, Inc.   STREET ADDRESS   728 134th St SW , Suite 128				
CITY, STATE, ZIP CODE, COUNT		TYPE ESTABLISHMENT INSPECTED			
Everett, WA 9	8204	Producer of sterile drug products			
* *	scoloration was observed on the mL in the ISO 5 (b) (4) LFH #	(b) (	(4) (b)	vial rack hold (4)	ing Sodium
OBSERVATIO	ON 4				
Placement and/o	or use of non-sterile material within	the ISO 5 a	rea. Spec	ifically,	
A) Opened non-sealing packages of sterile (b) (4) was observed used in the cleaning of ISO 5 (b) (4) LFHs. The (b) (4) were also observed used in disinfecting of drug components prior to use in the ISO 5 (b) (4) LFHs.					
B) Non-sterile production of haz	(b) (4) is used to cover the ardous drugs.	work surfac	es of ISO	(b) (4)	for the
C) On 5/8/17, 5/9/17, 5/10/17, and 5/12/17 the sleeves of the non-sterile gowns worn by Technicians were observed touching the work benches within the ISO 5 (b) (4) LFHs during sterile drug production.					
OBSERVATIO	ON 5				
There is no cleaning of the dust-collecting areas in the area surrounding the ISO 5 area. For example:					
Apparent dust and black particles were observed on the ISO 7 surface directly underneath the fluorescent lights for ISO 5 (b) (4) LFH # (b) (4) (b) (4)					
	AMENDMENT 2				
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Tracy K Li, Investigator			S/19/2017  X Tracy K Li Tracy K U Investigator Super by: Tracy K U-S	DATE ISSUED 5/19/2017

INSPECTIONAL OBSERVATIONS

PAGE 2 OF 5 PAGES

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

	DEPARTMENT OF HEAL FOOD AND DRU	TH AND HUMA G ADMINISTRATIO			
Bothell, WA 9	HONE NUMBER Ave SE Suite 210 98021		DATE(S) OF INSPECTION 5/8/2017-5/18/2017* FEI NUMBER 3009486960		
NAME AND TITLE OF INDIVIDUA					
FIRM NAME	, Sr Director of Operations	STREET ADDRESS			
Option Care I	Enterprises, Inc.	728 134th	n St SW , Suite 128		
Everett, WA 9		Producer of sterile drug products			
OBSERVATIO	ON 6				
verified under o	d areas were not certified under deperational conditions. Specifically,				
(b) (4) , see (b) (4) ;	ies performed on 5/5/16 and 11/2/19 erial no. (b) (4); (b) (4) [ (b) (4) LFH # (b) (4) r dynamic conditions. For example:	LFH # ( <b>4</b> )	(b) (4) LFH # (b) (4) ; serial no. (b) (	(b) (4) 4) were not	
your smoke stude containers and containers	tudy conducted on 5/5/16 was not only video which shows the absence of closures in each of the LFHs. A most formed in each LFH.	of production	n equipment, drug comp	oonents,	
LFH # equipment	(b) (4)  (b) (4)  (b) (4)  (c) You did not perform parental parenteral nutrition dr	a mock fill u	which houses the pro	•	
OBSERVATIO	ON 7				
appropriately t	lates for environmental monitoring of ensure your production process that they are suitable for sterile drug	s and prod	luction facility do no		
	AMEN	IDMENT 2			
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Tracy K Li, Investigator		X Tracy K Li Tracy K Li Investigator Signed by: Tracy K. Li -S	DATE ISSUED 5/19/2017	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	SPECTIONAL O	1 2 2 2	PAGE 3 OF 5 PAGES	

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHON	PHONE NUMBER		DATE(S) OF INSPECTION		
Bothell, WA	Ave SE Suite 210 . 98021		5/8/2017-5/18/2017* FEI NUMBER		
	-0340 Fax:(425)302-0404		3009486	5960	
NAME AND TITLE OF INDIVIDUA	AL TO WHOM REPORT ISSUED				
_	, Sr Director of Operations				
FIRM NAME		STREET ADDRESS		~ !! 100	
Option Care I	Enterprises, Inc.	728 134th St SW , Suite 128			
Everett, WA 9	98204	Producer of sterile drug products			cts
incubator was of the manufacture incubation whice environmental services and the services and the services are services.  A) SOP P164 P describes "media (b) (4) F] for an additional fills on 8 under the temporal bands additional days (b) (4) surface samples specification.	ch states, "[i]ncubate exposed plates samples and personnel samples were ersonnel Training and Evaluation in furn and low risk" media fill runs where constant and low risk media fill runs where the constant and low risk me	for Englished Special (b) (4) see the control of th	anipulation of these meteorification of the the these meteorification of the thes	tal Monitoring ins  (4) °F] for (b) (4) h  on Skills; revised 4  are incubated at (b) (4) ° Celsi med "medium and dia-filled units we h.  neubation of medi ere collected on 4) These not the establishe	inge is below truction for ***". These  1/15/17 b) (4) us { (b) (4) ° 1 low risk" re incubated a plates for by storage for (b) (4) viable air and d
describes the monitoring of media plates for gloved fingertip sampling as "(b) (4) Celsius (b) (4)					
F] for hours followed by monitoring at (b) (4) C) for diditional days." (b) (4)					
employees performed gloved fingertip sampling on (b) (4), (b) (4), (c) these samples were incubated under the temperature of "" F which is not the					
(b) (4); these samples were incubated under the temperature of "F which is not the established specification.					
established specification.					
AMENDMENT 2					
	EMPLOYEE(S) SIGNATURE				DATE ISSUED
SEE REVERSE	Tracy K Li, Investigator			5/19/2017	5/19/2017
OF THIS PAGE				Tracy K Li	
				Investigator Signed by: Tracy K. Li -S	

INSPECTIONAL OBSERVATIONS

PAGE 4 OF 5 PAGES

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION		
22215  26th Ave SE Suite 210	5/8/2017-5/18/2017*		
Bothell, WA 98021	FEI NUMBER		
(425)302-0340 Fax: (425)302-0404	3009486960		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED			
Mary K. Moe , Sr Director of Operations			
FIRM NAME	STREET ADDRESS		
Option Care Enterprises, Inc.	728 134th St SW , Suite 128		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Everett, WA 98204	Producer of sterile drug products		

## **OBSERVATION 8**

There is no record for monitoring of pressure differentials between adjacent rooms in the Compounding Area and no record for cleaning when drugs were produced on the weekends. These drug productions were:

- A) Drug produced on 2/12/17: Rx (b)(6),(b)(7)(C) Cefepime 2 g/20 mL SW syringe (IV push).
- B) Drugs produced on 3/26/17: Rx (b)(6),(b)(7)(C) Vancomycin 1 g/100 mL NS eclipse; Rx (b)(6),(b)(7)(C) Vancomycin 1.5 g/250 mL NS eclipse.
- C) Drug produced on 4/16/17: Rx (b)(6),(b)(7)(C) Ertapenem 1 g/100 mL NS Mini-Bag Plus (Invanz)

## \*DATES OF INSPECTION

5/08/2017(Mon),5/09/2017(Tue),5/10/2017(Wed),5/12/2017(Fri),5/18/2017(Thu)

## **AMENDMENT 2**

	5/19/2017  X Tracy K Li Tracy K U Investigator Signed by: Tracy K. US	DATE ISSUED 5/19/2017
--	---	-----------------------